PRESS INQUIRIES

Mapp Biopharmaceutical, Inc.

We develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.

 

In the News

BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin

January 13, 2021

MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure

June 11, 2019

Experimental antibody ‘cocktail’ protects animals from three deadly Ebola viruses

January 11, 2019

PBS Newshour

PBS NewsHour – How to grow an Ebola vaccine with a tobacco plant
November 23, 2015

Publications

Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin.            Feb 13, 2020

Rescue of rhesus macaques from the lethality of aerosolized ricin toxin.
Jan 10, 2019
Mapp Bio Publications

A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.
Jan 9, 2019

Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
Jan 9, 2019

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.
Apr 05, 2017

Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses,.
Apr, 2017

De Novo MS/MS Sequencing of Native Human Antibodies.
Oct 25, 2016

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.
Oct 13, 2016

Monoclonal antibody therapy for Junin virus infection.
Apr 4, 2016

Antibody therapeutics for Ebola virus disease.
January 27, 2016

READ MORE

© 2017 Mapp Biopharmaceautical - Leaf Bio. All Rights Reserved.